Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05565313 · ClinicalTrials.gov registry record
Predicting Radiological Extranodal Extension in Oropharyngeal Carcinoma Patients Using AI
A clinical trial of Head and Neck Carcinoma, sponsored by Maastricht Radiation Oncology.
- Active
- Registry status
- 900
- Enrollment target
- 3
- Study locations
NCT05565313: Active study of Head and Neck Carcinoma, sponsored by Maastricht Radiation Oncology.
NCT05565313 is a study of Head and Neck Carcinoma that is active but no longer recruiting, run by Maastricht Radiation Oncology. The registered enrollment target is 900 participants, above the 383-participant average among 30 other Head and Neck Carcinoma trials with a reported enrollment target (135% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05565313, a study of Head and Neck Carcinoma, is active but no longer recruiting, sponsored by Maastricht Radiation Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 3
- Study locations
Study Summary
Development and validation of a model that predicts rENE from radiological imaging using annotated / labeled scans by means of deep learning
Primary Outcome
The performance of the model will be evaluated in terms of discrimination through the Harrell's C-index and the area (AUC) under the receiver operator curve (ROC) in predicting rENE.
Conditions Studied
Study Locations (3)
Massachusetts
- Harvard Medical School and clinical faculty at Dana-Farber Cancer Institute/Brigham and Women's Hospital - Boston
Ontario
- Princess Margaret Cancer Centre - Toronto
Limburg
- Maastro - Maastricht
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2026-08-01 |
What the registry record for NCT05565313 still lists
NCT05565313 is an observational study that tracks outcomes without assigning an intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 383-participant average among 30 other Head and Neck Carcinoma trials with a reported enrollment target (135% higher).
The record links to 1 condition, with Head and Neck Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT05565313 reports a single indexed study location in Massachusetts, Ontario, Limburg.
Frequently Asked Questions
What is clinical trial NCT05565313 about?
NCT05565313 is a clinical study titled "Predicting Radiological Extranodal Extension in Oropharyngeal Carcinoma Patients Using AI". Development and validation of a model that predicts rENE from radiological imaging using annotated / labeled scans by means of deep learning
What is the current status of trial NCT05565313?
This trial is currently active not recruiting. The enrollment target is 900 participants. The study started on 2022-03-22. Estimated completion is 2026-08-01.
What conditions does trial NCT05565313 study?
This clinical trial studies the following conditions: Head and Neck Carcinoma.
Who is sponsoring clinical trial NCT05565313?
This trial is sponsored by Maastricht Radiation Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05565313 being conducted?
This trial has 3 study locations across Massachusetts, Ontario, Limburg. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05565313's enrollment target sits among peer trials
900 4th of 30 higher than 27 of 30 other Head and Neck Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
RECRUITING · Phase 1
-
A Financial Intervention (Financial Compass) to Identify and Address Financial Hardship Among Head and Neck Cancer Patients, Financial Compass Trial
RECRUITING · NA
-
Tongue-out Radiation Therapy (TORT) for the Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck Cancer
RECRUITING · NA
-
Cancer Genetic Testing in Ethnic Populations
RECRUITING · NA
-
Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI